Cases & Deals

Cellectis and AstraZeneca enter into research collaboration and agree on equity investment of up to $220 million by AstraZeneca

Client(s) Cellectis SA

Jones Day advised Cellectis in connection with the joint research collaboration agreement entered into with AstraZeneca and initial equity investment by AstraZeneca into Cellectis of $80 million. A potential additional equity investment of $140 million is subject to the approval of the extraordinary general meeting of the shareholders of Cellectis to be held on December 22, 2023, clearance from the French Ministry of Economy according to French foreign direct investment regulations, and other customary closing conditions.